这篇稿子的核心重点，不是“基因组测序本身”，而是研究 鲍曼不动杆菌（A. baumannii）如何依靠 RND 外排泵来耐受人类用的非抗生素药物，尤其聚焦两个外排系统：AdeABC 和 AdeIJK。作者想回答的问题是：这些经典的耐药外排泵，除了排出抗生素之外，是否也能把抗抑郁药、抗精神病药、抗肿瘤药、NSAIDs 等“非抗生素”排出去，从而帮助细菌存活。
更具体地说，这篇文章的主线有四层。第一层，是证明 AdeABC 和 AdeIJK 都参与非抗生素耐受。作者构建了不同的敲除株，在 ATCC19606 和 AYE 两个背景下做药敏比较，发现删掉这些外排泵后，细菌对多种非抗生素更敏感，说明这些泵确实在帮助细菌抵抗这类药物。
第二层，是说明 AdeABC 和 AdeIJK 的底物偏好不一样，也就是“分工不同”。文中结果显示，AdeABC 更偏向外排疏水性高、极性低的分子，例如一些抗抑郁药、部分酚噻嗪类抗精神病药和 diphenhydramine；而 AdeIJK 更偏向处理极性更高、氢键能力更强的分子，比如一些抗肿瘤药、部分 NSAIDs 和其他较高极性的非抗生素。换句话说，这篇文章的一个重要贡献，是把“RND 外排泵能排非抗生素”进一步细化成“不同泵对不同化学性质分子有选择性”。
第三层，是讨论 这些非抗生素不仅是外排底物，还可能诱导耐药基因表达。作者做了 qPCR，发现不同非抗生素会以药物依赖的方式诱导 adeB 或 adeJ 的表达；其中 mitomycin C 还会同时诱导 craA，提示 AdeIJK 和 CraA 之间可能存在协同外排。也就是说，文章不只是在看“药物能不能被排出去”，还在看“药物会不会反过来刺激细菌把外排系统开得更强”。这和“非抗生素促进交叉耐药”这个大问题直接相关。
第四层，是从 化学性质和结构机制 上解释为什么 AdeABC 和 AdeIJK 会偏好不同底物。作者把药物的 XlogP、TPSA、氢键供体/受体等理化参数与表型做相关分析，又结合 AdeB / AdeJ 的分子对接，提出：AdeB 的结合口袋更偏疏水，因此更适合疏水、低极性分子；AdeJ 的口袋更偏极性、带电，更容易与高极性、能形成更多氢键的分子相互作用。 这部分是文章的“机制解释”，用来支撑前面的药敏现象。
所以，如果用中文简单概括整篇稿子的“focus”，可以说：
这篇论文主要研究鲍曼不动杆菌的 RND 外排泵 AdeABC 和 AdeIJK 如何介导对非抗生素药物的天然耐受，并进一步揭示两者在底物选择性、诱导表达和结构基础上的差异。 它想传达的中心信息是：非抗生素药物也可能被细菌识别并外排，甚至还能诱导外排泵表达，因此它们可能成为促进多重耐药和交叉耐药的选择压力。
顺便提醒你一句：从这篇稿子的结构来看，whole genome sequencing 不是论文主角，只是用来辅助验证某个突变株构建是否正确、是否存在额外突变；真正的主线仍然是 非抗生素耐受表型、外排泵表达调控、以及底物识别机制。
如果你愿意，我可以下一步直接帮你把这篇文章概括成一段适合组会汇报的中文摘要。
Not really. As the manuscript is written now, the three genomes named in 2.8 are not all clearly used in the Results.
What is clear:
- In 2.8 Whole genome sequencing, you say that A. baumannii ATCC19606 wildtype, ATCC19606 ΔadeABΔadeIJ, and ATCC19606 ΔadeIJK were sequenced, assembled, annotated, checked for circular plasmids, and analyzed by ANI.
- In the Results, the only explicit use of WGS is for the ATCC19606 ΔadeIJK mutant: the text says WGS confirmed no off-target mutations and that an adeK fragment was still present.
- The ATCC19606 wildtype genome is not explicitly used as a new sequencing result. The statement about the absence of adeC in ATCC19606 is supported by Nemec et al. 2007, not by your new WGS.
- The ΔadeABΔadeIJ strain appears in the Results only as a phenotypic comparator in susceptibility/NPN experiments, not as an explicitly discussed genome/assembly result.
So the practical answer is:
- ΔadeIJK genome: yes, clearly used
- ATCC19606 wildtype genome: not clearly used in Results
- ΔadeABΔadeIJ genome: not clearly used in Results
Another issue is that ANI, assembly statistics, and plasmid findings are described in Methods, but I do not see those outputs actually reported in the Results text you shared.
My hint for revision: You should either
- keep 2.8 but add Results text explaining how the WT and ΔadeABΔadeIJ genomes were used, or
- narrow 2.8 so it reflects only the genome that is actually used in the paper, mainly the ΔadeIJK mutant validation.
A stronger Results sentence could be something like:
Whole-genome sequencing was primarily used to validate the ATCC19606 ΔadeIJK mutant, confirming the intended deletion, excluding additional off-target mutations, and detecting retention of an adeK fragment.
And if WT and ΔadeABΔadeIJ were also truly used, add one sentence such as:
The WT and ΔadeABΔadeIJ assemblies were used as reference genomes for comparison of deletion boundaries / plasmid content / ANI / secondary mutations.
Right now, that use is not visible in the manuscript.
One more point: the wording around ΔadeIJ, ΔadeIJK, and partial adeK deletion is a bit confusing in Results, so readers may not immediately understand which sequenced mutant is being discussed.
I can help you draft a revised version of section 2.8 and the matching Results sentence.